Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S. market in the third quarter of 2025. International rollouts are expected to ...

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

The FDA approved Tryptyr to treat the signs and symptoms of dry eye disease, according to a press release from Alcon. Tryptyr ...

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first ...

Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).